Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is not only responsible for receptor binding and virus fusion, but also a major Ag among the SARS-CoV proteins that induces protective Ab responses. In this study, we showed that the S protein of SARS-CoV is highly immunogenic during infection and immunizations, and contains five linear immunodominant sites (sites I to V) as determined by Pepscan analysis with a set of synthetic peptides overlapping the entire S protein sequence against the convalescent sera from SARS patients and antisera from small animals immunized with inactivated SARS-CoV. Site IV located in the middle region of the S protein (residues 528–635) is a major immunodominant epitope. The synthetic peptide S603–634, which overlaps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the 30 serum samples from healthy blood donors, suggesting its potential application as an Ag for developing SARS diagnostics. This study also provides information useful for designing SARS vaccines and understanding the SARS pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Self-citationIdentification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Coronavirus Spike Proteins in Viral Entry and Pathogenesis
Gallagher, T. M., & Buchmeier, M. J. (2001) · Virology · doi:10.1006/viro.2000.0757 · Cited by 658
Holmes, K. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmp030078 · Cited by 330
Cited by
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02232-10 · Cited by 1,108
Self-citationChan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496
“As described in the previous publication (23), the used peptide pools, which overlap the site IV sequence in the S protein, were identified to react with the convalescent sera of former SARS patients but with none of the samples from healthy blood donors, suggesting the justification for their use in eliciting SARS-Co…”
BackgroundSerological assays for emerging coronaviruses: Challenges and pitfalls
Meyer, B., Drosten, C., & Müller, M. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.03.018 · Cited by 410
Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J. M., Nelson, P. S., Pöhlmann, S., & Soilleux, E. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035876 · Cited by 398
Bertram, S., Glowacka, I., Müller, M. A., Lavender, H., Gnirss, K., Nehlmeier, I., Niemeyer, D., He, Y., Simmons, G., Drosten, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05300-11 · Cited by 329
Self-citationModified Vaccinia Virus Ankara
Volz, A., & Sutter, G. (2017) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.07.001 · Cited by 323
Li, W., Wong, S.-K., Li, F., Kuhn, J. H., Huang, I.-C., Choe, H., & Farzan, M. (2006) · Journal of Virology · doi:10.1128/jvi.80.9.4211-4219.2006 · Cited by 276
Self-citationTepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates
Paul, S., Sidney, J., Sette, A., & Peters, B. (2016) · Current Protocols in Immunology · doi:10.1002/cpim.12 · Cited by 274
Receptor recognition and cross-species infections of SARS coronavirus
Li, F. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.08.014 · Cited by 268
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135
“(Hayward, CA), as previously described (20).”
BackgroundMethodInfluentialSelf-citationA human SARS-CoV neutralizing antibody against epitope on S2 protein
Duan, J., Yan, X., Guo, X., Cao, W., Han, W., Qi, C., Feng, J., Yang, D., Gao, G., & Jin, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.089 · Cited by 114
“It has been shown that spike (S) protein of SARS-CoV is not only responsible for binding to its receptor angiotensin-converting enzyme 2 (ACE2) that initiates entry into host cell [9] [10] [11] [12] , but has also been identified as a dominant antigenic determinant eliciting neutralizing antibody during the infection…”
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Metadata
- Authors
- He, Y., Zhou, Y., Wu, H., Luo, B., Chen, J., Li, W., & Jiang, S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09
- Volume
- 173
- Issue
- 6
- Pages
- 4050-4057
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2151539653
- Cited by
- 143
- References
- 4
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.